Company Overview and News
Cellmid Limited’s (ASX:CDY) wholly owned subsidiary Advangen has entered into an exclusive agreement to distribute its évolis® anti-aging hair care products in the Peoples Republic of China.
Cellmid Ltd (ASX:CDY) has secured a new premium retail partnership with leading US retailer, Bloomingdales, for its évolis® Professional product range.
Cellmid Limited (ASX:CDY) has reported a record quarter of receipts of $2.2 million in the three months ending March 31, 2018.
Cellmid Limited (ASX:CDY) CEO Maria Halasz provides a show and tell updating Proactive Investors on progress and strategies for the company’s international portfolio of products, including the world’s first non-injectable filler product.
Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.
Cellmid Limited (ASX:CDY) is one of the more diversified ASX-listed biopharmaceutical groups with prominent products in the health and well-being sectors as well as traditional clinical markets.
Cellmid Limited (ASX:CDY) has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina® in Australia and New Zealand for an initial period of up to five years.
Cellmid Limited (ASX:CDY) has been shown support from its board and management as Maria Halasz, managing director and CEO, has increased her holding in the company.
Cellmid Limited (ASX:CDY) has achieved key milestones and operational targets for the quarter ended 31 December 2017.
Cellmid Limited (ASX:CDY) has received $1 million in the form of a strategic investment from US based investor, Dennis Eck.
Cellmid Limited (ASX:CDY) has signed a master supply agreement with YPB Group Ltd (ASX:YPB) to market the company’s évolis hair loss products in China.
Cellmid Ltd (ASX:CDY) has been busy this week showcasing the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.
Cellmid Ltd (ASX:CDY) just last month appointed the experienced Dr Martin Cross as a non-executive director, a highly regarded pharmaceutical executive with over 30 years’ experience.
Cellmid (ASX:CDY) will be presenting the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.
Cellmid Ltd (ASX:CDY) continues its global roll-out and has now opened its first Advangen Hair Biology concept store in Tokyo, Japan.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...